Amplia Therapeutics completes single-dose study of AMP945Pharmaceuticals company Amplia Therapeutics (ATX) has successfully completed a single dose study of its proprietary focal adhesion kinase (FAK) inhibitor AMP945.To view media story please click here. Posted on March 17th, 2021 . Updated on September 16th, 2021 by Amplia Therapeutics